cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer
Objective: To describe cell-free DNA (cfDNA)-inferred putative clonal hematopoiesis (CH) candidates during first-line platinum-based chemotherapy followed by poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer.Methods: In SCRUM-Japan MONSTAR-SCREEN-1, we analyzed clinically reported paired tumor tissue and plasma cfDNA profiling (324-gene assays).Baseline (B1) data were assessed in 35 treatment-naïve patients; longitudinal cfDNA was available at B1, after platinum without progression (B2), and during/after PARPi without progression (B3) in 8 patients.Putative CH candidates were defined as pathogenic variants (variant allele frequency <40%) in prespecified CH-related genes detected in plasma but not detected in matched tumor tissue at clinical reporting thresholds.
Authors
- Kenichi Harano (ORCID: https://orcid.org/0000-0002-0833-3489)
- Daisuke Aoki (ORCID: https://orcid.org/0000-0002-9596-8326)
- Yoshiaki Nakamura (ORCID: https://orcid.org/0000-0002-5241-6855)
- Kiyoko Kato (ORCID: https://orcid.org/0000-0003-0047-7637)
- Tatsuyuki Chiyoda (ORCID: https://orcid.org/0000-0002-8214-2242)
- Kimihiko Ito (ORCID: https://orcid.org/0000-0002-3115-7997)
- Hidemichi Watari (ORCID: https://orcid.org/0000-0002-4189-6187)
- Kazuhiro Takehara (ORCID: https://orcid.org/0000-0001-8808-3338)
- Hideaki Bando (ORCID: https://orcid.org/0000-0001-5041-2765)
- Tomomi Egawa‐Takata (ORCID: https://orcid.org/0000-0003-3088-1091)
- Takao Fujisawa (ORCID: https://orcid.org/0009-0002-3438-5757)
- Shogen Boku (ORCID: https://orcid.org/0000-0002-5015-0379)
- Takayuki Yoshino (ORCID: https://orcid.org/0000-0002-0489-4756)
- Masanori Isobe (ORCID: https://orcid.org/0000-0002-5899-9932)
- Daisuke Shintani (ORCID: https://orcid.org/0000-0001-6689-8915)
- Kei Ihira (ORCID: https://orcid.org/0000-0002-2927-2072)
- Kosei Hasegawa (ORCID: https://orcid.org/0000-0002-1903-7001)
- Hiromichi Nakajima (ORCID: https://orcid.org/0000-0001-6401-4258)
- Hiroshi Yagi (ORCID: https://orcid.org/0000-0003-3295-2068)
- Mika Okazawa‐Sakai (ORCID: https://orcid.org/0000-0002-6439-856X)
- Yoh Hayasaki (ORCID: https://orcid.org/0009-0007-2000-1181)
- Ichinosuke Hyodo (ORCID: https://orcid.org/0000-0001-8210-0731)
Institutions
- Kansai Medical University (JP)
- Kyushu University (JP)
- Keio University (JP)
- Kansai Rosai Hospital (JP)
- Saitama International Medical Center (JP)
- Shikoku Cancer Center (JP)
- Hokkaido University Hospital (JP)
- National Cancer Center Hospital East (JP)
- Gifu University (JP)
- International University of Health and Welfare (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2026-08-03
- DOI
- https://doi.org/10.3802/jgo.2027.38.e11
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00